New therapies in metastatic castration resistant prostate cancer

Constance Thibault; Christophe Massard

doi:10.1016/j.bulcan.2015.04.016

New therapies in metastatic castration resistant prostate cancer

Titre traduit de la contribution: Les nouvelles thérapies dans le cancer de la prostate métastatique

Constance Thibault, Christophe Massard

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

6 Citations (Scopus)

Résumé

Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.

Titre traduit de la contribution	Les nouvelles thérapies dans le cancer de la prostate métastatique
langue originale	Anglais
Pages (de - à)	501-508
Nombre de pages	8
journal	Bulletin du Cancer
Volume	102
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.bulcan.2015.04.016
état	Publié - 1 juin 2015

Accès au document

10.1016/j.bulcan.2015.04.016

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{5e05e05d0db54c60ab9f7277d9925266,

title = "New therapies in metastatic castration resistant prostate cancer",

abstract = "Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.",

keywords = "Abiraterone, CRPC, Cabozantinib, Enzalutamide, MOSCATO",

author = "Constance Thibault and Christophe Massard",

note = "Publisher Copyright: {\textcopyright} 2015 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.bulcan.2015.04.016",

language = "English",

volume = "102",

pages = "501--508",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "6",

}

TY - JOUR

T1 - New therapies in metastatic castration resistant prostate cancer

AU - Thibault, Constance

AU - Massard, Christophe

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.

AB - Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.

KW - Abiraterone

KW - CRPC

KW - Cabozantinib

KW - Enzalutamide

KW - MOSCATO

UR - http://www.scopus.com/inward/record.url?scp=84983388788&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2015.04.016

DO - 10.1016/j.bulcan.2015.04.016

M3 - Review article

C2 - 26022286

AN - SCOPUS:84983388788

SN - 0007-4551

VL - 102

SP - 501

EP - 508

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 6

ER -